<DOC>
	<DOCNO>NCT02175056</DOCNO>
	<brief_summary>The study design trial Dose-Block Randomized , Placebo control ( Double-blind ) , Active Controlled ( Open-label ) , Dose-escalation .</brief_summary>
	<brief_title>A Dose-Block Randomized , Placebo Controlled ( Double-blind ) , Active Controlled ( Open-label ) , Dose-escalation Study</brief_title>
	<detailed_description>- Extended vivo half-life HL2351 also anticipate provide improve therapeutic efficacy base sustained maintenance effective concentration . - A safety concern may address utilize IL-1Ra use get approval EMA US FDA know relatively safe , Fc fusion technology already apply various therapeutic agent .</detailed_description>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>1 . A healthy adult man age 20 45 year ( inclusive ) screen 2 . Weight 55 90 kg ( inclusive ) body mass index ( BMI ) 18.0 27.0 ( inclusive ) BMI ( kg/m2 ) = Body weight ( kg ) / { height ( ) } 2 3 . Voluntary consent participation study signature IRBapproved inform consent form explain characteristic clinical study , prior screen test 1 . Current history clinically significant hepatic , renal , neurological , immunological , respiratory endocrine disease hematological oncological disease , cardiovascular disease psychiatric disease ( mood disorder compulsive disorder , etc . ) ( case hepatic disease , hepatitis virusinfected subject may also include ) 2 . Hypersensitivity drug ( aspirin antibiotic , etc . ) past history clinically significant hypersensitivity 3 . In sit vital sign measure rest 3 min , systolic blood pressure &lt; 90mmHg &gt; 150mmHg , diastolic blood pressure &lt; 60mmHg &gt; 100 mmHg 4 . Past history drug abuse positive urine drug screen result 5 . Use prescription medicine oriental medicine within 2 week use overthecounter ( OTC ) medication vitamin preparation within 1 week prior schedule first dose ( however , subject may include condition satisfy , discretion investigator ) 6 . Participation another clinical study administration drug within 3 month prior schedule first dose ( dose day ) 7 . Whole blood donation within 2 month apheresis within 1 month prior schedule first dose , transfusion within 1 month prior first dose 8 . A habitual drinker ( &gt; 21 units/week , 1 unit = 10 g pure alcohol ) person abstain alcohol consumption hospitalization 9 . A smoker 10 cigarettes/day average past 3 month person abstain smoke hospitalization 10 . A person plan get pregnant study practice acceptable contraception ( example : surgical sterilization subject partner , intrauterine device use partner , barrier contraception , diaphragm condom use combination ) even plan get pregnant 11. Notable prolongation QT/QTcb interval screening ( e.g. , repeat confirmation QTcb interval &gt; 450 m ) 12 . Confirmed history risk factor TdP ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) 13 . Chronic , uncontrolled symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosis ) 14 . Pyrexia ≥38°C within 1 week prior administration investigational product 15 . Past history tuberculosis infection and/or positive Quantiferon TBGold test result screen 16 . A person participate study receive investigational product 17 . A person otherwise determine eligible clinical study participation investigator due reason include clinical laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>First In Human</keyword>
	<keyword>CAPS , SoJIA , AOSD , Bechet Disease , Rheumatoid arthritis</keyword>
</DOC>